Evidence map›Paper›PMID 26865709›Full record

ArticleJournal of virology2016

Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus Vectors.

Sanford L Boye, Antonette Bennett, Miranda L Scalabrino, K Tyler McCullough, Kim Van Vliet, Shreyasi Choudhury, Qing Ruan, James Peterson, Mavis Agbandje-McKenna, Shannon E Boye

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: A comprehensive review.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
  8. Retinal Penetrating Adeno-Associated Virus.Investigative ophthalmology & visual science · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Developing New Vectors for Retinal Gene Therapy.Cold Spring Harbor perspectives in medicine · 2023
    Article
  15. Preclinical studies in support of phase I/II clinical trials to treatMolecular therapy. Methods & clinical development · 2023
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sanford L BoyeDepartment of Ophthalmology, College of Medicine, University of Florida, Gainesville, Florida, USA.
Antonette BennettDepartment of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida, USA.
Miranda L ScalabrinoDepartment of Ophthalmology, College of Medicine, University of Florida, Gainesville, Florida, USA.
K Tyler McCulloughDepartment of Ophthalmology, College of Medicine, University of Florida, Gainesville, Florida, USA.
Kim Van VlietDepartment of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida, USA.
Shreyasi ChoudhuryDepartment of Ophthalmology, College of Medicine, University of Florida, Gainesville, Florida, USA.
Qing RuanDepartment of Ophthalmology, College of Medicine, University of Florida, Gainesville, Florida, USA.
James PetersonDepartment of Ophthalmology, College of Medicine, University of Florida, Gainesville, Florida, USA.
Mavis Agbandje-McKennaDepartment of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, Florida, USA mckenna@ufl.edu Shannon.Boye@eye.ufl.edu.
Shannon E BoyeDepartment of Ophthalmology, College of Medicine, University of Florida, Gainesville, Florida, USA mckenna@ufl.edu Shannon.Boye@eye.ufl.edu.
University of Florida · US

Funding

Engineering AAV for safe and efficient gene delivery to the human retinaR01EY024280 · NEI · UNIVERSITY OF FLORIDA · PI Shannon Elizabeth Boye · 2014 to 2026
$7.5M
RESEARCH TRAINING IN VISION SCIENCET32EY007132 · NEI · UNIVERSITY OF FLORIDA · PI W CLAY SMITH · 1991 to 2026
$3.8M
Vision Research CoreP30EY021721 · NEI · UNIVERSITY OF FLORIDA · PI HAUSWIRTH, WILLIAM W · 2011 to 2015
$2.8M
NEI NIH HHS P30 EY021721NEI NIH HHS P30EY021721NEI NIH HHS R01 EY024280NEI NIH HHS R01EY024280NEI NIH HHS T32 EY007132
6 · The paper itself

Abstract

unlabelledAdeno-associated viruses (AAVs) currently are being developed to efficiently transduce the retina following noninvasive, intravitreal (Ivt) injection. However, a major barrier encountered by intravitreally delivered AAVs is the inner limiting membrane (ILM), a basement membrane rich in heparan sulfate (HS) proteoglycan. The goal of this study was to determine the impact of HS binding on retinal transduction by Ivt-delivered AAVs. The heparin affinities of AAV2-based tyrosine-to-phenylalanine (Y-F) and threonine-to-valine (T-V) capsid mutants, designed to avoid proteasomal degradation during cellular trafficking, were established. In addition, the impact of grafting HS binding residues onto AAV1, AAV5, and AAV8(Y733F) as well as ablation of HS binding by AAV2-based vectors on retinal transduction was investigated. Finally, the potential relationship between thermal stability of AAV2-based capsids and Ivt-mediated transduction was explored. The results show that the Y-F and T-V AAV2 capsid mutants bind heparin but with slightly reduced affinity relative to that of AAV2. The grafting of HS binding increased Ivt transduction by AAV1 but not by AAV5 or AAV8(Y733F). The substitution of any canonical HS binding residues ablated Ivt-mediated transduction by AAV2-based vectors. However, these same HS variant vectors displayed efficient retinal transduction when delivered subretinally. Notably, a variant devoid of canonical HS binding residues, AAV2(4pMut)ΔHS, was remarkably efficient at transducing photoreceptors. The disparate AAV phenotypes indicate that HS binding, while critical for AAV2-based vectors, is not the sole determinant for transduction via the Ivt route. Finally, Y-F and T-V mutations alter capsid stability, with a potential relationship existing between stability and improvements in retinal transduction by Ivt injection. IMPORTANCE: AAV has emerged as the vector of choice for gene delivery to the retina, with attention focused on developing vectors that can mediate transduction following noninvasive, intravitreal injection. HS binding has been postulated to play a role in intravitreally mediated transduction of retina. Our evaluation of the HS binding of AAV2-based variants and other AAV serotype vectors and the correlation of this property with transduction points to HS affinity as a factor controlling retinal transduction following Ivt delivery. However, HS binding is not the only requirement for improved Ivt-mediated transduction. We show that AAV2-based vectors lacking heparin binding transduce retina by subretinal injection and display a remarkable ability to transduce photoreceptors, indicating that other receptors are involved in this phenotype.

Indexed as

Genetic VectorsTransduction, GeneticAnimalsCapsidDependovirusHEK293 CellsHeparan SulfateHumansInjections, IntraocularInjections, IntravenousLiverMice, Inbred BALB CMice, Inbred C57BLMutationPhotoreceptor Cells, VertebrateReassortant VirusesHeparan Sulfate

Identifiers

PMID26865709
PMCPMC4810560
OpenAlexW2319893601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.